A 48-year-old male proband presented with atypical chest pain. An echocardiogram revealed possible left ventricular apical noncompaction that was confirmed by cardiac magnetic resonance imaging as left ventricular noncompaction cardiomyopathy (LVNC; Figure 1A ). His ejection fraction was initially preserved at 60% but declined to 45% over the subsequent 6 years despite optimal medical therapy. His asymptomatic 19-year-old son was diagnosed with LVNC at the time of a screening echocardiogram, and follow-up cardiac magnetic resonance imaging confirmed the diagnosis ( Figure 1B ). His ejection fraction was 50% at the time of diagnosis and was subsequently stable for 5 years with medical therapy. An echocardiogram from the proband's father showed normal left ventricular structure and function with no excess trabeculation ( Figure 1C and 1D) . The proband's daughter had a normal echocardiogram. There were no other family members with a known history of cardiomyopathy or heart failure ( Figure 1E ).
GENETIC TESTING
A standard dilated cardiomyopathy panel genetic test (27 genes) on a sample from the proband revealed no pathogenic mutations. Whole-exome sequencing was then performed for the proband, his parents, and his son. Analysis of whole-exome sequencing demonstrated 2 variants that were considered to be potentially causative. The first, GATA4 c.778 C>T, Arg260Trp, was present in the proband, his son, and his unaffected father ( Figure 1E ). The GATA4 variant is absent in the Genome Aggregation Database. Furthermore, MutationTaster predicts that it is likely pathogenic, and the locus is a highly conserved site adjacent to a PKG-1α (protein kinase G 1α) phosphorylation target (Ser262) 1 in the nuclear localization signaling domain of the protein (Figure 2A and 2B ). Given this supportive evidence and the importance of GATA4 in cardiac development, we selected the GATA4 variant for functional testing.
The second potentially causative variant was a de novo variant in PTEN (c.517C>T, p. Arg173Cys), present only in the proband and his son and not present in either of the proband's parents ( Figure 1E ). This particular variant is already known to be a pathogenic mutation causative of Phosphatidlylinositol-3,4,5-triphosphate 3-phosphatase (PTEN) hamartoma tumor syndrome 2 and is absent from the Genome Aggregation Database. PTEN hamartoma tumor syndrome is characterized by dermatologic findings, as well as benign and malignant tumors of the thyroid, breast, and endometrium. However, cardiac manifestations of PTEN mutations have not been reported. Clinical genetics evaluation revealed characteristic macrocephaly in both the proband and his son, but no other manifestations of PTHS. The proband was found to have a single 6-mm adenoma on colonoscopy, and no evidence of malignancy on thyroid and renal screening. PTEN is expressed in the heart throughout life and undergoes a regulatory transition from a highly phosphorylated state during fetal growth to an unphosphorylated state in the adult heart. [2] [3] [4] PTEN is a key modulator of the Phosphoinositide 3-kinase-Protein kinase B (PI3K-AKT) pathway that is essential for cardiac growth. 5 A third variant was found in junctophilin2 (JPH2), c.572 C>G, Pro191Arg, present in the proband, his son, and his father ( Figure 1E ). However, this variant is present at an allele frequency of 0.05% in Genome Aggregation Database, and in silico analysis suggests it is A, Schematic presentation of GATA4 and its domains. The Arg260 residue locates in the nuclear localization signaling (NLS) domain, adjacent to the PKG-1α (protein kinase G 1α) phosphorylation site (Ser262). B, Arg260 and Cys271 residues (highlighted in red) are evolutionarily conserved across all vertebrates. The PKG-1α binding motifs are underlined. C, Immunoblot showing that wild-type (WT) and mutant GATA4 were present at a similar level in transfected HEK293A cells, n=2 experiments. D, Immunofluorescence demonstrating that both mutant of GATA4 correctly localized to the nucleus despite the mutations being in the NLS domain. E, GATA4 transcriptional activity measured in vivo by luciferase assay. WT GATA4 activated the atrial natriuretic factor promoter by 3.46-fold compared to empty vector alone. Both Arg260Trp and Cys271Ser mutant showed reduced activation at 2.42-and 1.24-fold, respectively (*P=0.0002 for WT vs Arg260Trp and **P<0.0001 for WT vs Cys271Ser, n=27).
likely benign, arguing against its pathogenicity. Although mutations in JPH2 have been reported in hypertrophic cardiomyopathy, a true association of JPH2 mutations with hypertrophic cardiomyopathy has recently been questioned. 6 Thus, although a partial contribution of this JPH2 variant cannot be completely excluded, based on the high frequency in the general population, we did not pursue further evaluation of this variant.
INVESTIGATION OF THE GATA4 ARG260TRP VARIANT
A recent study reported that the GATA4 mutation, Cys271Ser, is associated with dilated cardiomyopathy and reduces the DNA-binding affinity and transcriptional activity of GATA4. 7 Given the proximity of this mutation to the GATA4 Arg260Trp variant, we used the Cys271Ser mutation as a positive control.
Because the Arg260 and Cys271 residues are located in the nuclear localization signaling domain of the protein, we first tested whether mutations at these residues lead to nuclear mislocalization. We generated and expressed wild-type and mutant GATA4 in HEK293A cells (see Methods in the Data Supplement) and showed that they were expressed at similar level by immunoblot ( Figure 2C ). In addition, immunofluorescence revealed that both Arg260Trp and Cys271Ser mutants correctly localized to the nucleus ( Figure 2D ).
We next determined the transcriptional activity of wild-type and mutant GATA4 by a luciferase assay. The atrial natriuretic factor (NPPA) gene is a known target of GATA4. Therefore, we generated a reporter construct in which the firefly luciferase gene was under the control of the NPPA promoter. Wild-type or mutant GATA4 was cotransfected with the NPPA:luc reporter gene and with a Renilla luciferase construct to control for transfection efficiency (see Methods in the Data Supplement). As shown in Figure 2E , wild-type GATA4 activated transcription from the NPPA promoter 3.5±1.2-fold over empty vector alone. Comparatively, the Cys271Ser and Arg260Trp GATA4 mutants both showed reduced levels of transcription activation (1.2±0.4-fold, P<0.0001, and 2.4±1.2-fold over empty vector, P=0.0002, respectively).
DISCUSSION AND CONCLUSIONS
LVNC is an inherited cardiomyopathy characterized by hypertrabeculation of the left ventricular myocardium and frequently left ventricular systolic dysfunction. 8 LVNC results from failure of the myocardium to compact during embryonic development and is defined by a noncompacted-to-compacted myocardium ratio of 2.3:1. Complications include progressive heart failure, arrhythmias, and thromboembolism. Despite being recognized as a primary genetic cardiomyopathy by the American Heart Association, only 17% to 40% of cases of LVNC have a known genetic cause. [9] [10] [11] This proportion is lower than in other inherited cardiomyopathies, including hypertrophic, dilated, and arrhythmogenic right ventricular cardiomyopathy, for which ≈50% of the genetic basis is known. [12] [13] [14] Genes previously associated with LVNC have primarily been identified based on their association with hypertrophic and dilated cardiomyopathies (eg, MYH7, ACTC, TNNT2, and LMNA). 9, 15, 16 Although dysregulated myocardial development is thought to mark the origin of LVNC, 17, 18 cardiac developmental genes have not previously been reported as a cause of LVNC.
Here, we identified novel potential associations of both GATA4 and PTEN mutations with LVNC. Pathogenicity of the GATA4 variant is suggested by lack of background prevalence, in silico predictions, biological relevance, and functional evidence in this study that the mutation reduces transcriptional activity. Pathogenicity of the PTEN mutation has already been substantiated in PTEN hamartoma syndrome. Our finding of a mutation in PTEN, which is critical for normal cardiac regulation of the PI3K/AKT pathway, in the context of the mutation in GATA4 which is also known to regulate the same pathway, strongly implicates a novel digenic cause of LVNC.
In the current era of whole-exome and wholegenome sequencing, novel variants associated with genetic conditions are frequently identified; however, establishing disease causality is a significant challenge. The gold standard to establish a variant as pathogenic is demonstration of cosegregation in at least 5 family members. However, strong evidence of cosegregation is often not possible because of small family size, incomplete penetrance, and variable age of disease onset within single families. In the common circumstance when clinical criteria cannot be met, experimental functional data can be valuable in providing support for variant pathogenicity. In this study, we showed that GATA4 transcriptional activity is disrupted by the Arg260Trp variant, supporting its role as a disease-causing mutation. Given the critical role of GATA4 in cardiac development, the established association with GATA4 mutations and congenital heart disease, and the recent finding of a GATA4 mutation in a family with dilated cardiomyopathy, we propose that mutations in GATA4 may be an important contributor to LVNC and should be considered for inclusion in clinical testing panels.
The reduction in transcriptional activity of the Arg260Trp GATA4 suggests that the mutant protein may have lower DNA-binding affinity. The Arg260 residue is located in the linker between the 2 zinc-finger DNA-binding domains. Ma et al 1 showed that phosphorylation of a nearby residue, Ser262, by PKG-1α and physical association between GATA4 and PKG-1α increased its activation of the NPPA promoter by over a hundred-fold. Arg260 is part of the PKG-1α recog-nition motif, and a mutation at this site may interfere with PKG-1α binding. Thus, the reduced functional activity of the particular GATA4 mutant found in this study is biologically plausible.
Since its first association with atrial septal defects reported in 2003, 19 >20 mutations in GATA4 have been described. 7, [20] [21] [22] [23] [24] [25] [26] Many of these mutations are associated with atrial septal defects, ventricular septal defects, tetralogy of Fallot, and dilated cardiomyopathy. Other uncommon cardiac anomalies include endocardial cushion defects 23 and single ventricle. 24 All but one of the reported mutations are missense, and no mutation hotspots have been observed. Some mutations are also found to have incomplete penetrance, and unaffected carrier relatives have been identified. These observations suggest that the specific manifestations of GATA4 mutations might be influenced by genetic background and environmental factors. Indeed, Rajagopal et al 27 reported that C57 mice carrying a heterozygous Gly4Asp mutation in GATA4 were 20-fold more susceptible to endocardial cushion defects than FVB mice. This observation demonstrates that other genetic variation strongly influences the cardiac developmental phenotype. The range of phenotypes associated with GATA4 mutations could also arise, in part, through mutation-specific effects on the function or expression of GATA4 at different stages of cardiac development or growth.
In this study, we found that the GATA4 variant in the context of a PTEN mutation is the most likely cause of LVNC in this family. The proband's father carried the GATA4 variant without any evidence of LVNC even at older age. The evidently spontaneous PTEN mutation in the proband is, therefore, a plausible contributor to the development of LVNC in the proband and his son. PTEN is a key regulator of PI3K/AKT signaling, which is involved in cardiomyocyte differentiation and continues to be expressed in mature cardiomyocytes. Furthermore, Ang et al 28 recently reported that a missense mutation in GATA4, Gly296Ser, led to dysregulation of the PI3K/AKT signaling pathway in induced pluripotent stem cell-derived cardiomyocytes. Thus, mutations in both genes may have functional consequences that converge on the same pathway, with resultant LVNC and left ventricle systolic dysfunction. Digenic inheritance has been clearly described in a range of other genetic diseases, but not previously in the heart, to our knowledge. 29 Whole-exome and whole-genome sequencing opens the possibility of further identification of di-or multigenic causes of cardiomyopathy, and analysis algorithms to screen for potential causal variants in these studies should consider the possibility of mutations in multiple genes affecting converging pathways to cause disease.
We used a nonmuscle-specific cell line for functional testing because we were measuring transcriptional activity and not a cellular phenotype per se. One of our goals for this study was to serve as an example for relatively fast and inexpensive functional testing of putative disease-causing variants. Primary cardiac myocytes are not amenable to plasmid transfection and require the construction of viral vectors for ectopic gene expression which lengthens time and increases expense. However, the functional significance of this GATA4 variant, as well as its effects on the interaction between GATA4 and PTEN, should be confirmed in future studies in cardiac muscle cells in vitro and in vivo.
In conclusion, we identified mutations in GATA4 and PTEN as a potential digenic cause of LVNC through whole-exome sequencing. These mutations may have additive or synergistic effects in disrupting PI3K/AKT signaling that is critical for cardiac development and maintenance. Application of systematic approaches that consider pathway relationships in causal variant screening during whole-exome or whole-genome sequencing analysis may increase the likelihood of genetic discovery for inherited cardiomyopathies. 
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